Across the pond: Aurora looking to become even bigger fish in Europe’s medical cannabis market

Timing will ultimately depend on if rules allow for entry

Comments

With three global production facilities already certified as EU-GMP (European Union-Good Manufacturing Practice), the company's next undertaking is the certification of production in Denmark and Portugal. Uriel Sinai/Getty Images

Aurora Cannabis Inc. has taken another step toward cementing its positioning in Europe’s medical cannabis market, ensuring the company is ready to enter new markets as regulatory barriers fall and demand rises.

With three global production facilities already certified as EU-GMP (European Union-Good Manufacturing Practice), the company’s next undertaking is the certification of production in Denmark and Portugal.

Aurora Europe, a subsidiary of Aurora Cannabis Inc., is now the largest authorized importer, exporter and distributor of medical cannabis in Europe, a company statement notes. Aurora, which has operations in 24 countries, broke new ground in February, becoming one of the first Canadian companies to commercially supply cannabis-based medicines in the U.K. It also won a public tender in Germany in April, enabling the company to cultivate and distribute cannabis in Germany.

Aurora is now the largest authorized importer, exporter and distributor of medical cannabis in Europe.

“We’re seeing changes happening in Europe,” Laura Gallant, Aurora’s senior media strategist, says of the growing support for medical cannabis. Gallant attributes these changes in Europe to shifts in public opinion in favour of medical cannabis legalization.

Announced this week as a headline sponsor for medical cannabis conference Cannabis Europe, Gallant says Aurora is eager to break new barriers worldwide.

But expansion, ultimately, depends on whether or not existing regulations on medical cannabis change.While governments in France, Germany, Luxemburg and Portugal are reassessing their access programs and official stances on the medicinal benefits of cannabis, legal roadblocks remain elsewhere.

“As regulations evolve throughout Europe and the rest of the world, Aurora will continue to evolve with them,” says Jonathan Zaid, Aurora’s director of advocacy and corporate social responsibility.

There is no intention of moving away from its home base in Canada, Zaid says. Pointing out that “the majority of our team is in Canada,” he nonetheless adds, “we intend to continue growth to provide patients access to medical cannabis worldwide.”

Cam Battley, the company’s chief corporate officer, says “Aurora began out of commitment to expand patient access to medical cannabis, and we have remained dedicated to furthering the international movement ever since.”

 

Want to keep up to date on what’s happening in the world of cannabis?  Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.